中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页
机构
成果
学者
登录
注册
登陆
×
验证码:
换一张
忘记密码?
记住我
×
校外用户登录
CAS IR Grid
机构
合肥物质科学研究院 [3]
金属研究所 [1]
采集方式
OAI收割 [4]
内容类型
期刊论文 [4]
发表日期
2017 [1]
2015 [1]
2011 [1]
2010 [1]
学科主题
筛选
浏览/检索结果:
共4条,第1-4条
帮助
条数/页:
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
排序方式:
请选择
题名升序
题名降序
提交时间升序
提交时间降序
作者升序
作者降序
发表日期升序
发表日期降序
Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice
期刊论文
OAI收割
JOURNAL OF ZHEJIANG UNIVERSITY-SCIENCE B, 2017, 卷号: 18
-
  |  
收藏
  |  
浏览/下载:14/0
  |  
提交时间:2020/10/26
RANDOMIZED PHASE-III
NEOADJUVANT CHEMOTHERAPY
ENCAPSULATED DOXORUBICIN
1ST-LINE CHEMOTHERAPY
PROGNOSTIC MARKER
PLUS DOCETAXEL
COMBINATION
CYCLOPHOSPHAMIDE
TRASTUZUMAB
PACLITAXEL
Liposomal doxorubicin
Breast cancer
Adjuvant chemotherapy
Therapeutic effect
Toxic and side effects
microRNA-218 promotes gemcitabine sensitivity in human pancreatic cancer cells by regulating HMGB1 expression
期刊论文
OAI收割
CHINESE JOURNAL OF CANCER RESEARCH, 2015, 卷号: 27, 期号: 3, 页码: 267-278
作者:
Liu Zhe
;
Du Ruixia
;
Long Jin
;
Guo Kejian
;
Ge Chunlin
  |  
收藏
  |  
浏览/下载:21/0
  |  
提交时间:2021/02/26
GROUP BOX 1
PLUS GEMCITABINE
OVARIAN-CANCER
ADENOCARCINOMA
THERAPY
RESISTANCE
DOCETAXEL
AUTOPHAGY
TARGET
CHEMOTHERAPY
Pancreatic cancer
microRNA-218 (miR-218)
gemcitabine (GEM)
apoptosis
high mobility group box 1 (HMGB1)
Long-term outcomes of gemcitabine and cisplatin in patients with recurrent or metastatic esophageal squamous cell carcinoma: a phase II trial
期刊论文
OAI收割
CHINESE MEDICAL JOURNAL, 2011, 卷号: 124
-
  |  
收藏
  |  
浏览/下载:23/0
  |  
提交时间:2020/10/26
PLUS CISPLATIN
ONCOLOGY-GROUP
CANCER
CHEMOTHERAPY
DOCETAXEL
chemotherapy
gemcitabine
cisplatin
esophageal cancer
Capecitabine combined with weekly docetaxel in Chinese patients > 65 years with anthracycline-resistant metastatic breast cancer
期刊论文
OAI收割
CHINESE MEDICAL JOURNAL, 2010, 卷号: 123
-
  |  
收藏
  |  
浏览/下载:13/0
  |  
提交时间:2020/10/26
PHASE-III TRIAL
PLUS DOCETAXEL
MULTICENTER
THERAPY
PHOSPHORYLASE
TOLERABILITY
PACLITAXEL
XELODA(R)
SURVIVAL
capecitabine
weekly docetaxel
metastatic breast cancer
anthracycline
elderly
tolerability